Our peer-reviewed research on RestoreU was featured by https://t.co/pEghUxMHcC.
The study followed 345 patients, exploring cognitive outcomes in real-world clinical care.
Read more: https://t.co/NXuWqwvqQf
#uMETHODHealth#HealthcareAI#CognitiveHealth
Multidomain cognitive care has a real-world challenge: implementation.
uMETHOD Health’s newly published study explores how clinical decision support can bring personalized cognitive care into routine practice.
Read the study: https://t.co/fh2AZtM5GM
#CognitiveHealth
Why is early cognitive decline so often missed?
uMETHOD Health co-founders Vik Chandra and John Q. Walker II, PhD discuss the challenges of cognitive care and how clinical decision support can help.
Watch the full conversation: https://t.co/Qyt4uW7cGZ
#uMETHODHealth
17.5M Americans age 65+ live with mild cognitive impairment or dementia.
Coming soon to YouTube: uMETHOD Health co-founders Vik Chandra and John Q. Walker II, PhD discuss how clinical decision support and AI can help make complex cognitive care actionable.
#uMETHODHealth
New research from uMETHOD Health is now published in Current Aging Science.
83.5% of patients maintained or improved their cognitive stage over a mean 14.1 months (N=345).
Real-world evidence for multidomain cognitive care.
Read the study: https://t.co/fh2AZtM5GM
A cognitive assessment takes one visit. The clinical story behind it can take decades to build.
uMETHOD turns longitudinal patient data into actionable insights, evaluating 50+ treatable contributors to cognitive decline.
#uMETHODHealth#CognitiveCare
The APS2 blood test had high diagnostic accuracy for identifying Alzheimer disease among individuals w/ cognitive symptoms in primary and secondary care, providing superior performance vs the diagnostic accuracy after standard clinical evaluation. https://t.co/o98dmrWXZw
The FNIH comparison of leading Alzheimer's blood tests is now published. Tests were from C2N, Fujirebio, ALZPath, Janssen, Roche and Quanterix. Plasma %p-tau217/p-tau217 best predicted amyloid and tau PET, brain volumes, and dementia.
#ENDAlz#FNIH
https://t.co/vEiUlxLvus
In adults without cognitive impairment and with low brain Aβ levels, a blood test combining p-tau217 and Aβ42/40 better predicted longitudinal changes in brain Aβ load than individual biomarkers.
https://t.co/tK74g0SZC5
@biofinder_study
Another tech giant is working hard to bring something in their AI portfolio to healthcare.
- foundation models for medical imaging
- a healthcare data analysis platform
- to build an AI documentation product geared toward nurses.
https://t.co/asViLmXeNI
This is pretty interesting. UCL demographer’s work debunking ‘Blue Zone’ regions of exceptional lifespans wins Ig Nobel prize | IOE - Faculty of Education and Society - UCL – University College London https://t.co/73GH7OO3lk
New large study finds COVID may increase risk of heart attacks and strokes three years after infection.
Unlike other infections, the elevated heart risks from infection did not appear to diminish over time, a striking finding that the researchers say is "unique to COVID."
“The intervention comprises components such as psychoeducation, strengthening routine, light therapy, increased activity, exercise, and carer support. It is tailored to the needs of people with dementia and their relatives.”
ICYMI: New research, published in @LancetLongevity by @rapaport_penny, @Gill_Livingston & colleagues from @UCLPsychiatry, showed that a multicomponent intervention significantly enhanced sleep for those with #dementia, as well as their family carer.
https://t.co/Y4qG94HM8w
This summer, the design and baseline results paper of FINGER-NL was published. Today, Kay Deckers will present this work at the @AlzheimerEurope Conference #34AEC. Don’t miss his poster (POS1-03)!
Ramanan et al. examine the evolution of clinical phenotypes in patients diagnosed with Alzheimer's disease or FTLD, and show that behavioural and cognitive profiles of individuals with the same initial diagnosis can converge or diverge over time. https://t.co/RGUvl2wrAL
Wonderful recognition of basic and foundational discovery science on #microRNA done in a 'simple' model organism of #Celegans as a stepping stone for translational work and #NobelPrize2024.